Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Metabolism and Disposition of Vilanterol, a Long-Acting β2-Adrenoceptor Agonist for Inhalation Use in Humans

Andrew W. Harrell, Sarah K. Siederer, Jo Bal, Nainesh H. Patel, Graeme C. Young, Clive C. Felgate, Sebastian J. Pearce, Andy D. Roberts, Claire Beaumont, Amanda J. Emmons, Adrian I. Pereira and Rodger D. Kempsford
Drug Metabolism and Disposition January 2013, 41 (1) 89-100; DOI: https://doi.org/10.1124/dmd.112.048603
Andrew W. Harrell
Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Research and Development, Ware, Hertfordshire, United Kingdom (A.W.H., N.H.P., G.C.Y., C.C.F., S.J.P., A.D.R., C.B., A.I.P.); Clinical Pharmacology or Medicines Discovery Research, GlaxoSmithKline Research and Development Ltd., Stevenage, Hertfordshire, United Kingdom (A.J.E., S.K.S., R.D.K.); and Medicines Discovery and Development, GlaxoSmithKline Research and Development, Stockley Park, Middlesex, United Kingdom (J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah K. Siederer
Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Research and Development, Ware, Hertfordshire, United Kingdom (A.W.H., N.H.P., G.C.Y., C.C.F., S.J.P., A.D.R., C.B., A.I.P.); Clinical Pharmacology or Medicines Discovery Research, GlaxoSmithKline Research and Development Ltd., Stevenage, Hertfordshire, United Kingdom (A.J.E., S.K.S., R.D.K.); and Medicines Discovery and Development, GlaxoSmithKline Research and Development, Stockley Park, Middlesex, United Kingdom (J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jo Bal
Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Research and Development, Ware, Hertfordshire, United Kingdom (A.W.H., N.H.P., G.C.Y., C.C.F., S.J.P., A.D.R., C.B., A.I.P.); Clinical Pharmacology or Medicines Discovery Research, GlaxoSmithKline Research and Development Ltd., Stevenage, Hertfordshire, United Kingdom (A.J.E., S.K.S., R.D.K.); and Medicines Discovery and Development, GlaxoSmithKline Research and Development, Stockley Park, Middlesex, United Kingdom (J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nainesh H. Patel
Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Research and Development, Ware, Hertfordshire, United Kingdom (A.W.H., N.H.P., G.C.Y., C.C.F., S.J.P., A.D.R., C.B., A.I.P.); Clinical Pharmacology or Medicines Discovery Research, GlaxoSmithKline Research and Development Ltd., Stevenage, Hertfordshire, United Kingdom (A.J.E., S.K.S., R.D.K.); and Medicines Discovery and Development, GlaxoSmithKline Research and Development, Stockley Park, Middlesex, United Kingdom (J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graeme C. Young
Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Research and Development, Ware, Hertfordshire, United Kingdom (A.W.H., N.H.P., G.C.Y., C.C.F., S.J.P., A.D.R., C.B., A.I.P.); Clinical Pharmacology or Medicines Discovery Research, GlaxoSmithKline Research and Development Ltd., Stevenage, Hertfordshire, United Kingdom (A.J.E., S.K.S., R.D.K.); and Medicines Discovery and Development, GlaxoSmithKline Research and Development, Stockley Park, Middlesex, United Kingdom (J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clive C. Felgate
Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Research and Development, Ware, Hertfordshire, United Kingdom (A.W.H., N.H.P., G.C.Y., C.C.F., S.J.P., A.D.R., C.B., A.I.P.); Clinical Pharmacology or Medicines Discovery Research, GlaxoSmithKline Research and Development Ltd., Stevenage, Hertfordshire, United Kingdom (A.J.E., S.K.S., R.D.K.); and Medicines Discovery and Development, GlaxoSmithKline Research and Development, Stockley Park, Middlesex, United Kingdom (J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian J. Pearce
Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Research and Development, Ware, Hertfordshire, United Kingdom (A.W.H., N.H.P., G.C.Y., C.C.F., S.J.P., A.D.R., C.B., A.I.P.); Clinical Pharmacology or Medicines Discovery Research, GlaxoSmithKline Research and Development Ltd., Stevenage, Hertfordshire, United Kingdom (A.J.E., S.K.S., R.D.K.); and Medicines Discovery and Development, GlaxoSmithKline Research and Development, Stockley Park, Middlesex, United Kingdom (J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andy D. Roberts
Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Research and Development, Ware, Hertfordshire, United Kingdom (A.W.H., N.H.P., G.C.Y., C.C.F., S.J.P., A.D.R., C.B., A.I.P.); Clinical Pharmacology or Medicines Discovery Research, GlaxoSmithKline Research and Development Ltd., Stevenage, Hertfordshire, United Kingdom (A.J.E., S.K.S., R.D.K.); and Medicines Discovery and Development, GlaxoSmithKline Research and Development, Stockley Park, Middlesex, United Kingdom (J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Beaumont
Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Research and Development, Ware, Hertfordshire, United Kingdom (A.W.H., N.H.P., G.C.Y., C.C.F., S.J.P., A.D.R., C.B., A.I.P.); Clinical Pharmacology or Medicines Discovery Research, GlaxoSmithKline Research and Development Ltd., Stevenage, Hertfordshire, United Kingdom (A.J.E., S.K.S., R.D.K.); and Medicines Discovery and Development, GlaxoSmithKline Research and Development, Stockley Park, Middlesex, United Kingdom (J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda J. Emmons
Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Research and Development, Ware, Hertfordshire, United Kingdom (A.W.H., N.H.P., G.C.Y., C.C.F., S.J.P., A.D.R., C.B., A.I.P.); Clinical Pharmacology or Medicines Discovery Research, GlaxoSmithKline Research and Development Ltd., Stevenage, Hertfordshire, United Kingdom (A.J.E., S.K.S., R.D.K.); and Medicines Discovery and Development, GlaxoSmithKline Research and Development, Stockley Park, Middlesex, United Kingdom (J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrian I. Pereira
Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Research and Development, Ware, Hertfordshire, United Kingdom (A.W.H., N.H.P., G.C.Y., C.C.F., S.J.P., A.D.R., C.B., A.I.P.); Clinical Pharmacology or Medicines Discovery Research, GlaxoSmithKline Research and Development Ltd., Stevenage, Hertfordshire, United Kingdom (A.J.E., S.K.S., R.D.K.); and Medicines Discovery and Development, GlaxoSmithKline Research and Development, Stockley Park, Middlesex, United Kingdom (J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodger D. Kempsford
Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Research and Development, Ware, Hertfordshire, United Kingdom (A.W.H., N.H.P., G.C.Y., C.C.F., S.J.P., A.D.R., C.B., A.I.P.); Clinical Pharmacology or Medicines Discovery Research, GlaxoSmithKline Research and Development Ltd., Stevenage, Hertfordshire, United Kingdom (A.J.E., S.K.S., R.D.K.); and Medicines Discovery and Development, GlaxoSmithKline Research and Development, Stockley Park, Middlesex, United Kingdom (J.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The metabolism and disposition of vilanterol, a novel long-acting β2-adrenoceptor agonist (LABA) for inhalation use, was investigated after oral administration in humans. Single oral administrations of up to 500 μg of vilanterol were shown to be safe and well tolerated in two clinical studies in healthy men. In a human radiolabel study, six healthy men received a single oral dose of 200 μg of [14C]vilanterol (74 kBq). Plasma, urine, and feces were collected up to 168 hours after the dose and were analyzed for vilanterol, metabolites, and radioactivity. At least 50% of the radioactive dose was orally absorbed. The primary route of excretion of drug-related material was via O-dealkylation to metabolites, which were mainly excreted in urine. Vilanterol represented a very small percentage (<0.5%) of the total drug-related material in plasma, indicative of extensive first-pass metabolism. Circulating metabolites resulted mainly from O-dealkylation and exhibited negligible pharmacologic activity. The therapeutic dose level for vilanterol is 25 μg by the inhalation route. At this low-dose level, the likelihood of pharmacologically inactive metabolites causing unexpected toxicity is negligible. In addition to providing an assessment of the disposition of vilanterol in human, this work highlights a number of complexities associated with determining human absorption, distribution, metabolism, and excretion (ADME) for inhaled molecules—mainly related to the low chemical doses and complications associated with the inhalation route of administration.

Footnotes

  • This work was funded by GlaxoSmithKline R&D, UK, as part of the development program for vilanterol as a novel therapeutic agent. Data in this manuscript correspond with clinical study numbers B2C106180 (GSK company report GM2009/00020/00) and B2C106181 (GSK company report YM2010/00088/00) with metabolite identifications reported in study number 10DMW020 (GSK company report 2011N115614). Hepatocyte incubations were reported in GSK company report WD2006/02574/00. Pharmacologic activities of metabolites were reported in GSK company report HR2008/00016/00. All authors were employees of GlaxoSmithKline Research and Development Ltd. at the time of conducting the work.

  • Primary Laboratory of Origin: Drug Metabolism and Pharmacokinetics Division, GlaxoSmithKline Research and Development Ltd., Park Road, Ware, United Kingdom

  • dx.doi.org/10.1124/dmd.112.048603.

  • Received August 30, 2012.
  • Accepted October 4, 2012.
  • Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 41 (1)
Drug Metabolism and Disposition
Vol. 41, Issue 1
1 Jan 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Metabolism and Disposition of Vilanterol, a Long-Acting β2-Adrenoceptor Agonist for Inhalation Use in Humans
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Metabolism and Disposition of Vilanterol in Human

Andrew W. Harrell, Sarah K. Siederer, Jo Bal, Nainesh H. Patel, Graeme C. Young, Clive C. Felgate, Sebastian J. Pearce, Andy D. Roberts, Claire Beaumont, Amanda J. Emmons, Adrian I. Pereira and Rodger D. Kempsford
Drug Metabolism and Disposition January 1, 2013, 41 (1) 89-100; DOI: https://doi.org/10.1124/dmd.112.048603

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Metabolism and Disposition of Vilanterol in Human

Andrew W. Harrell, Sarah K. Siederer, Jo Bal, Nainesh H. Patel, Graeme C. Young, Clive C. Felgate, Sebastian J. Pearce, Andy D. Roberts, Claire Beaumont, Amanda J. Emmons, Adrian I. Pereira and Rodger D. Kempsford
Drug Metabolism and Disposition January 1, 2013, 41 (1) 89-100; DOI: https://doi.org/10.1124/dmd.112.048603
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Humanized PXR-CAR-CYP3A4/7 Mouse as Model of Induction
  • Ozanimod Human Metabolism and Disposition
  • Clearance Pathways: Fevipiprant with Probenecid Perpetrator
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics